Crinetics Pharmaceuticals CRNX Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Crinetics Pharmaceuticals's business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Crinetics Pharmaceuticals's business segments — R&D?
- Crinetics Pharmaceuticals (CRNX) reported business segments — R&D of $100.08M in Q1 2026.
- How has Crinetics Pharmaceuticals's business segments — R&D changed year-over-year?
- Crinetics Pharmaceuticals's business segments — R&D increased by 31.3% year-over-year, from $76.24M to $100.08M.
- What does business segments — R&D mean?
- This metric represents the total aggregate expenditure on research and development activities across the entire business segment. It is a critical indicator of the company's investment in innovation and its commitment to advancing its drug pipeline. For clinical-stage companies, this is often the primary driver of operating cash burn.